Par Drugs & Chemical Intrinsic Value
Par Drugs & Chemical (PAR) median intrinsic value is ₹165.00 from 9 valuation models (range ₹98–₹249), vs current price ₹91.06 — +81.2% upside (Trading Below Calculated Value), margin of safety 44.8%. For current market price and key ratios, visit PAR stock overview.
PAR Valuation Methods Summary — DCF, Graham Number & P/E
Par Drugs & Chemical intrinsic value across 9 models vs current price ₹91.06 — upside/downside and value range per method. Browse Par Drugs & Chemical financial data for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹248.60 | ₹198.88 - ₹298.32 | +173.0% | EPS: ₹11.30, Sector P/E: 22x |
| Book Value Method | asset | ₹165.00 | ₹148.50 - ₹181.50 | +81.2% | Book Value/Share: ₹82.50, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹182.12 | ₹163.91 - ₹200.33 | +100.0% | Revenue/Share: ₹92.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹182.12 | ₹163.91 - ₹200.33 | +100.0% | EBITDA: ₹23.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹136.16 | ₹108.93 - ₹163.39 | +49.5% | CF Growth: 7.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹97.88 | ₹88.09 - ₹107.67 | +7.5% | EPS Growth: 10.8%, Fair P/E: 8.7x |
| Growth Adjusted P/E | growth | ₹178.23 | ₹160.41 - ₹196.05 | +95.7% | Revenue Growth: 10.3%, Adj P/E: 15.8x |
| ROE Based Valuation | profitability | ₹140.00 | ₹126.00 - ₹154.00 | +53.7% | ROE: 14.1%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹144.83 | ₹130.35 - ₹159.31 | +59.0% | EPS: ₹11.30, BVPS: ₹82.50 |
PAR Intrinsic Value vs Market Price — All Valuation Models
Par Drugs & Chemical fair value range ₹98–₹249 vs current market price ₹91.06 across 9 valuation models. Compare with PAR fair price to assess whether the stock is under or overvalued.
PAR Intrinsic Value Analysis — Undervalued or Overvalued?
Par Drugs & Chemical median intrinsic value ₹165.00, current price ₹91.06 — Trading Below Calculated Value by 81.2%, margin of safety 44.8%.
What is the intrinsic value of PAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Par Drugs & Chemical (PAR) is ₹165.00 (median value). With the current market price of ₹91.06, this represents a +81.2% variance from our estimated fair value.
The valuation range spans from ₹97.88 to ₹248.60, indicating ₹97.88 - ₹248.60.
Is PAR undervalued or overvalued?
Based on our multi-method analysis, Par Drugs & Chemical (PAR) appears to be trading below calculated value by approximately 81.2%.
PAR Financial Health — Key Ratios vs Industry Benchmarks
Par Drugs & Chemical financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.75 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.1% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.93x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PAR Cash Flow Quality — Operating & Free Cash Flow
Par Drugs & Chemical operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹16 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹20 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹10 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹8 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹12 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |